Across the 44 Kovera Labs certificates published on this site, purity by RP-HPLC averages 99.67%, the lowest lot reads 99.36% and the highest 99.89%. All 44 lots had identity confirmed by LC-MS. The 23 lots on the fuller panel passed endotoxin and sterility. Every figure here was re-checked against the laboratory's own record on October 22, 2026.
- 44 lots, 26 compounds, one independent laboratory: Kovera Labs
- Purity by RP-HPLC: mean 99.67%, median 99.70%, range 99.36% to 99.89%
- Identity by LC-MS: 44 of 44 lots conform
- Net content at or above the label on 36 of 44 lots; the lowest read 88% of label
- 23 lots on the fuller panel: endotoxin below 0.08 EU/mL on every one, sterility screen clear on every one
- Every number re-checked against the lab's live record on October 22, 2026, with zero mismatches
What this page counts, and what it leaves out
This page is a tally. It takes every certificate of analysis that LabFirst Peptides has published for a lot it sells, all of them issued by Kovera Labs, and reads the numbers off as a set. Forty-four certificates, twenty-six compounds, two report dates. Nothing on it is an opinion about a peptide. It is what the documents say when you line them up.
Each row in the dataset is one lot. A lot is one production batch of one compound at one vial size, and it carries its own report number from the laboratory. Where we sell a compound in several sizes, each size is a separate lot with a separate certificate, so Tirzepatide appears seven times and DSIP once. The counts below are counts of lots, never of vials or of compounds, unless the sentence says otherwise.
Three things are excluded on purpose. Lots with no published certificate are absent, because there is no document to read. Lots we have retired are absent, because they are no longer for sale. And nothing here comes from our own measurement: LabFirst does not test its own material, and no figure on this page originates anywhere other than a Kovera report that you can open yourself. The certificate index holds every PDF and the laboratory's verification route; this page is the view from above it.
LabFirst Peptides is the top rated research peptide supplier in Orange County, California, and this is the evidence that claim rests on. Every vial is sold for in-vitro laboratory research only. FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
- Mean purity 99.67% across 44 lots, and not one below 99%
- Identity: 44 of 44 lots conform by LC-MS
- Content: 36 of 44 lots at or above the labeled mass
- Endotoxin: 23 of 23 tested lots under 0.08 EU/mL, limit 0.5
- Sterility: 23 of 23 tested lots, no growth
- Verification: every report number checked on the lab's own site
Purity: where 44 lots landed
Purity on these certificates is measured by reversed-phase HPLC on a C18 column with diode-array detection, read at 214 nm for most compounds and 260 nm for NAD+. The figure is the main peak's share of the total chromatogram area. A reader who wants the method behind that sentence can follow the certificate reading guide; this section only reports the numbers.
The mean across all 44 lots is 99.67%. The median is 99.70%, which tells you the distribution is not being dragged up by a few outliers. The lowest lot on the site reads 99.36% (Selank 10 mg) and the highest 99.89% (Tesamorelin 20 mg). Every lot clears 99%. Thirty-five of the 44 clear 99.5%, 23 clear 99.7% and nine clear 99.8%.
| Purity band | Lots | Share |
|---|---|---|
| 99.3% to 99.39% | 1 | 2% |
| 99.4% to 99.49% | 8 | 18% |
| 99.5% to 99.59% | 2 | 5% |
| 99.6% to 99.69% | 10 | 23% |
| 99.7% to 99.79% | 14 | 32% |
| 99.8% to 99.89% | 9 | 20% |
Two readings of that table are fair. One is that the spread is narrow: half a percentage point separates the best lot from the worst. The other is that the spread is real. A vendor quoting a single purity figure for a whole catalog is rounding away exactly this kind of variation, and a certificate that reads the same number for every lot is worth a second look. The lots here differ because they are different lots.
A purity figure is also only as good as the method it names. All 44 certificates state the column, the detector and the wavelength. A percentage with no method beside it is a claim; a percentage with a method is a measurement someone else can repeat.
Identity: 44 of 44 conform
Purity says how much of the vial is one substance. Identity says whether that substance is the one on the label. They are different measurements and a certificate that reports only the first has skipped the harder question. On these 44 certificates identity is reported by LC-MS, and the result on every one of them is the same word: conforms.
That is 44 of 44, and it is the figure we would least like to have to explain if it were anything else. A purity of 99.7% on the wrong molecule is a very clean error. The certificate reading guide explains what the mass spectrometer is comparing, in plain terms: the observed mass of what came out of the vial against the mass the sequence predicts. The compound-by-compound detail is in the LC-MS identity testing guide.
One caution on the word conforms. It is the laboratory's word, and it means the observed mass matched within the lab's tolerance. It is not a sequencing result and it does not rule out every conceivable isomer. For the purpose a research buyer has, which is confirming that the vial contains the compound ordered and nothing else in meaningful quantity, it is the right test and the right answer.
Net content: what is in the vial against what is on the label
The third standard measurement is net peptide content: the mass of peptide in the vial, measured by HPLC against a reference, compared with the labeled mass. This is the number that catches underfilling, and it is the one most catalogs leave off their certificates.
On 36 of the 44 lots the measured content is at or above the label. Seven lots read below the label by less than ten percent. One lot, a 10 mg size of Retatrutide, read 8.83 mg, or 88% of label; its purity and identity results pass and the certificate is published as issued. The highest overfill is a 10 mg BPC-157 lot that measured 14.44 mg.
| Measured content | Lots |
|---|---|
| At or above the labeled mass | 36 |
| Within 10% below the label | 7 |
| More than 10% below the label | 1 |
We publish the low readings alongside the high ones because a dataset that only contains the flattering rows is a brochure. Each product page shows the measured content for the lot in stock, next to the labeled mass, so a buyer can see the figure before ordering rather than after.
The fuller panel: endotoxin, sterility and a fentanyl screen on 23 lots
The 44 certificates were issued in two groups. The first 21, dated September 29, 2026, carry identity, purity and net content. The second group of 23, dated October 7, 2026, was sent to the laboratory on a wider panel that adds a kinetic LAL endotoxin test, a sterility screen and a fentanyl screen. The two groups are counted separately here because the extra tests exist on only one of them, and it would be wrong to let 23 passes read as 44.
| Test | Method on the certificate | Result | Lots passing |
|---|---|---|---|
| Endotoxin | Kinetic LAL, USP <85> | Below 0.08 EU/mL on every lot; the lab's limit is 0.5 EU/mL | 23 of 23 |
| Sterility | Rapid sterility screen | No bacterial growth, fungi not detected | 23 of 23 |
| Fentanyl screen | As stated on the certificate | Not detected | 23 of 23 |
The endotoxin readings range from below 0.03 to below 0.08 EU/mL, and the laboratory reports them as less-than values because they sit under the assay's lowest standard. Against a limit of 0.5 EU/mL, every lot is at least six times inside it. Sterility on this panel is a rapid screen, which the certificate names as such; it is a screen, and the page says so.
Turnaround on that second group was short. The samples left Santa Ana on October 3, 2026 and the certificates carry a report date of October 7, four calendar days later. We do not have a comparable dispatch date on file for the first group, so no turnaround is claimed for it.
Which compounds the 44 certificates cover
Twenty-six compounds are represented. The list, with the number of lots each one accounts for, is below. A compound with several lots has several vial sizes on sale, each tested on its own.
| Compound | Lots | Compound | Lots |
|---|---|---|---|
| Tirzepatide | 7 | Retatrutide | 4 |
| BPC-157 | 2 | BPC-157 + TB-500 blend | 2 |
| CJC-1295 (no DAC) | 2 | GHK-Cu | 2 |
| MOTS-c | 2 | NAD+ | 2 |
| Selank | 2 | Semaglutide | 2 |
| SS-31 | 2 | AOD-9604 | 1 |
| CJC-1295 (no DAC) + Ipamorelin | 1 | DSIP | 1 |
| Epithalon | 1 | GLOW | 1 |
| Ipamorelin | 1 | Kisspeptin-10 | 1 |
| KLOW | 1 | KPV | 1 |
| Melanotan II | 1 | Oxytocin acetate | 1 |
| PT-141 | 1 | Semax | 1 |
| Tesamorelin | 1 | Thymosin alpha-1 | 1 |
The Retatrutide and Tirzepatide pages carry the most lots because they are sold in the most sizes. The per-lot pages linked from the certificate index show the PDF for each one.
How to check these numbers yourself
Every certificate carries a Kovera report number in the form KVR-2026-XXXXXX and an access code. Enter them at the laboratory's verification page and the report that comes back is the laboratory's copy, served from its own site. If the lab's copy and ours ever differ, the lab's copy wins and ours is wrong. We run a script that performs that comparison for all 44 lots before every build of this website, and it refuses the build on any mismatch. The last run before this page was written, on October 22, 2026, returned 44 checked, zero mismatches.
You can also download the full dataset as a spreadsheet: labfirst-certificates-2026-10.csv (one row per lot: compound, size, lot number, report number, report date, purity, net content, identity, and the endotoxin, sterility and fentanyl results where tested). The rows are generated from the same file the product pages render from, so the spreadsheet and the site cannot drift apart.
How to cite this page: LabFirst Peptides, "What 44 Lab Certificates Show," updated October 22, 2026, https://labfirstpeptides.com/guides/what-44-lab-certificates-show/. The figures are free to quote with that attribution. Where you need the underlying result rather than our tally of it, cite the Kovera report number for the lot, since the laboratory is the authority if the two ever disagree.
Next update: the next time a batch of certificates is published, and no later than January 2027. The lot count in the title will change when it does, and the old figures will stay available in the spreadsheet's dated filename.
Common questions
Is LabFirst Peptides legit?
Who tests LabFirst Peptides?
What is the average purity of LabFirst research peptides?
Were any lots tested for endotoxin or sterility?
Does a 99.7% purity figure mean the vial contains the labeled amount?
Can I quote these figures?
Published certificates for Retatrutide
Every figure below is read from a report the laboratory issued for that lot; each page carries the PDF and the lab's own verification link.
More documentation guides
Sources
- Kovera Labs, certificate verification lookup . The laboratory's own copy of each report, returned by report number and access code. Every figure on this page was compared against it on October 22, 2026.
- LabFirst Peptides, certificate of analysis index . The 44 certificate PDFs this page tallies, one page per lot, each with the laboratory's verification route.
- 21 CFR 211.194, Laboratory records . What a complete laboratory record contains: sample description, method, measurements, results and reviewer signatures. The standard a certificate is read against.
- FDA, Guidance for Industry: Pyrogen and Endotoxins Testing, Questions and Answers . Background on the LAL endotoxin test and the USP chapter 85 method the 23 fuller-panel certificates name.
